Lakefront Biotherapeutics (GLPGF) Change in Cash (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Change in Cash for 13 consecutive years, with -$25.5 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Change in Cash fell 153.68% year-over-year to -$25.5 million in Q1 2026; TTM through Mar 2026 was -$44.2 million, a 223.43% decrease from a year earlier, with the FY2025 full-year figure at $31.7 million, up 128.09% from the prior year.
• Change in Cash was -$25.5 million for Q1 2026 at Lakefront Biotherapeutics, down from $28.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $47.5 million in Q1 2025 and troughed at -$1.8 billion in Q4 2022.
• A 5-year average of -$291.4 million and a median of -$25.5 million in 2026 frame the typical range for Change in Cash.
• The widest YoY moves for Change in Cash: up 265.08% in 2025, down 2356.01% in 2025.
• Over 5 years, Change in Cash stood at -$1.8 billion in 2022, then jumped by 79.5% to -$365.6 million in 2023, then soared by 102.16% to $7.9 million in 2024, then jumped by 265.08% to $28.8 million in 2025, then tumbled by 188.41% to -$25.5 million in 2026.
• The last three Change in Cash figures came in at -$25.5 million (Q1 2026), $28.8 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.